Mounjaro vs Zepbound: The Same Molecule, Different FDA Indications, and What That Means for Your Prescription

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Mounjaro and Zepbound contain identical active ingredient (tirzepatide) at the same doses, manufactured by the same company (Eli Lilly)
• The only regulatory difference is FDA indication: Mounjaro approved for type 2 diabetes (2022), Zepbound approved for chronic weight management (2023)
• Insurance coverage differs dramatically based on diagnosis, not drug efficacy: diabetes plans cover Mounjaro, weight-loss coverage for Zepbound remains limited
• Prescribers can legally use either for either condition as off-label use, but pharmacy benefit managers often block claims based on diagnosis codes

Direct answer (40-60 words)

Mounjaro and Zepbound are the same drug. Both contain tirzepatide, a dual GLP-1/GIP receptor agonist, at identical doses (2.5 mg through 15 mg). Mounjaro received FDA approval for type 2 diabetes in May 2022. Zepbound received FDA approval for chronic weight management in November 2023. The molecular formulation, manufacturer, and side effect profile are identical.

Table of contents

1. The regulatory history: why one molecule has two brand names
2. Head-to-head comparison: formulation, dosing, and delivery
3. The clinical trial data behind each approval
4. Insurance coverage: the real difference that affects your wallet
5. What most articles get wrong about "different indications"
6. Off-label prescribing: when doctors write Mounjaro for weight loss
7. The compounded tirzepatide question: how it relates to both brands
8. Side effect profiles: identical mechanisms, identical risks
9. Which one should you ask for? The decision tree
10. The 2026 supply landscape and what it means for access
11. FAQ
12. Footer disclaimers

The regulatory history: why one molecule has two brand names

Tirzepatide is a synthetic peptide that activates both GLP-1 and GIP receptors. Eli Lilly developed it as LY3298176 in early-phase trials starting in 2014. The molecule showed dual benefits: significant A1C reduction in diabetic patients and substantial weight loss in both diabetic and non-diabetic populations.

Lilly made a strategic regulatory decision to pursue two separate FDA approval pathways rather than one broad indication. This is standard pharmaceutical strategy when a single drug has distinct clinical applications with different reimbursement landscapes.

Timeline:

• May 13, 2022: FDA approves tirzepatide as Mounjaro for type 2 diabetes based on the SURPASS trial program (SURPASS-1 through SURPASS-5)
• November 8, 2023: FDA approves the same tirzepatide formulation as Zepbound for chronic weight management in adults with BMI ≥30 or BMI ≥27 with weight-related comorbidities, based on the SURMOUNT trial program (SURMOUNT-1 through SURMOUNT-4)

The dual-brand strategy allows Lilly to market the same molecule under different value propositions, navigate separate insurance formularies, and price differently based on indication. Mounjaro's list price and Zepbound's list price are identical ($1,069.08 per month for maintenance doses as of April 2026), but rebate structures and coverage policies differ.

From a pharmacological standpoint, there is zero difference. The vials contain the same tirzepatide acetate salt, the same excipients (sodium chloride, sodium phosphate dibasic heptahydrate, water for injection), and the same pH buffer system. A 5 mg dose of Mounjaro is molecularly indistinguishable from a 5 mg dose of Zepbound.

Head-to-head comparison: formulation, dosing, and delivery

Feature	Mounjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly and Company	Eli Lilly and Company
FDA approval date	May 13, 2022	November 8, 2023
Approved indication	Type 2 diabetes mellitus	Chronic weight management
Available doses	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg	2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg
Delivery device	Single-dose prefilled pen	Single-dose prefilled pen
Injection frequency	Once weekly	Once weekly
Injection site	Subcutaneous (abdomen, thigh, upper arm)	Subcutaneous (abdomen, thigh, upper arm)
Titration schedule	Start 2.5 mg, increase by 2.5 mg every 4 weeks	Start 2.5 mg, increase by 2.5 mg every 4 weeks
Maximum dose	15 mg weekly	15 mg weekly
Excipients	Sodium chloride, sodium phosphate dibasic heptahydrate	Sodium chloride, sodium phosphate dibasic heptahydrate
Storage	Refrigerate 36°F to 46°F; can store at room temp up to 21 days	Refrigerate 36°F to 46°F; can store at room temp up to 21 days
List price (15 mg, 4-week supply)	$1,069.08	$1,069.08

The pens are visually distinct. Mounjaro pens have a blue base and label. Zepbound pens have a purple base and label. This cosmetic difference exists purely for brand differentiation and to reduce dispensing errors at the pharmacy level. The internal mechanism, needle gauge (32G), and injection volume are identical.

The clinical trial data behind each approval

Mounjaro's approval: the SURPASS program

The FDA approved Mounjaro based on five Phase 3 trials enrolling 6,600+ adults with type 2 diabetes:

• SURPASS-1 (Rosenstock et al., Lancet 2021): Tirzepatide monotherapy vs placebo. A1C reduction of 1.87% (5 mg), 1.89% (10 mg), 2.07% (15 mg) at 40 weeks. Weight loss of 7.0 kg, 7.8 kg, and 9.5 kg respectively.
• SURPASS-2 (Frías et al., NEJM 2021): Tirzepatide vs semaglutide 1 mg in diabetics. Tirzepatide 15 mg achieved 2.46% A1C reduction vs 1.86% for semaglutide. Weight loss: 12.4 kg vs 6.2 kg.
• SURPASS-3 (Ludvik et al., Lancet 2021): Tirzepatide vs insulin degludec. Superior A1C control and 10.9 kg weight loss vs 3.2 kg weight gain on insulin.
• SURPASS-4 (Del Prato et al., Lancet 2021): Cardiovascular safety trial. Tirzepatide showed non-inferiority to insulin glargine for major adverse cardiovascular events (MACE).
• SURPASS-5 (Dahl et al., Lancet Diabetes Endocrinol 2022): Tirzepatide added to insulin glargine. A1C reduction of 2.11% with 7.1 kg weight loss.

The FDA's approval letter for Mounjaro cites A1C reduction as the primary endpoint and weight loss as a secondary benefit. The label includes weight-loss data but positions Mounjaro as a glucose-control medication first.

Zepbound's approval: the SURMOUNT program

The FDA approved Zepbound based on four Phase 3 trials enrolling 4,400+ adults with obesity or overweight with comorbidities:

• SURMOUNT-1 (Jastreboff et al., NEJM 2022): Tirzepatide vs placebo in adults without diabetes. Mean weight loss at 72 weeks: 15.0% (5 mg), 19.5% (10 mg), 20.9% (15 mg) vs 3.1% placebo. This is the major trial for Zepbound.
• SURMOUNT-2 (Garvey et al., Lancet 2023): Tirzepatide in adults with obesity and type 2 diabetes. Weight loss: 12.8% (10 mg), 14.7% (15 mg) vs 3.2% placebo at 72 weeks.
• SURMOUNT-3 (Aronne et al., JAMA 2024): Weight-loss maintenance trial. Patients lost weight on tirzepatide for 36 weeks, then randomized to continue tirzepatide vs switch to placebo. Continued tirzepatide group lost an additional 5.5%, placebo group regained 14%.
• SURMOUNT-4 (Wadden et al., Nature Medicine 2023): Tirzepatide plus intensive behavioral therapy vs placebo plus therapy. Combined approach achieved 26.6% total body weight loss.

The FDA's approval letter for Zepbound cites percent total body weight loss as the primary endpoint. A1C reduction in the diabetic subgroup is noted but positioned as secondary.

The data is the same molecule in different populations. SURMOUNT enrolled non-diabetics and diabetics. SURPASS enrolled only diabetics. The weight-loss effect in diabetic patients is nearly identical across both programs. The A1C effect in SURMOUNT's diabetic subgroup mirrors SURPASS.

Insurance coverage: the real difference that affects your wallet

This is where the Mounjaro vs Zepbound distinction becomes financially material.

Mounjaro coverage (diabetes indication):

• Covered by 85% of commercial insurance plans as of April 2026 per IQVIA data
• Medicare Part D covers Mounjaro for type 2 diabetes under standard formulary rules
• Medicaid coverage varies by state but generally includes Mounjaro for diabetes
• Prior authorization typically requires documented A1C ≥7.0% or ≥8.0% depending on plan, plus failure of metformin or other first-line agents
• Average patient out-of-pocket cost after insurance: $25 to $75 per month with manufacturer savings card (Lilly offers up to $150/month off for commercially insured patients)

Zepbound coverage (weight management indication):

• Covered by approximately 25% of commercial insurance plans as of April 2026 per KFF analysis
• Medicare Part D explicitly excludes weight-loss medications by federal law (Social Security Act Section 1862)
• Medicaid coverage for weight-loss drugs exists in only 13 states as of 2026
• Prior authorization requires documented BMI ≥30 or BMI ≥27 with comorbidity, plus failure of lifestyle intervention
• Average patient out-of-pocket cost without insurance: $1,069.08 per month at list price; manufacturer savings card offers same $150/month off but rarely brings cost below $900/month for uninsured patients

The coverage gap exists because the Affordable Care Act does not mandate obesity treatment coverage the way it mandates diabetes coverage. Employers and insurers can exclude weight-loss medications from formularies without penalty. The result: identical drug, 60-percentage-point coverage difference based purely on diagnosis code.

The prior authorization game:

A patient with type 2 diabetes and obesity can get Mounjaro covered by submitting diabetes-related lab work (A1C, fasting glucose). The same patient asking for Zepbound will face denial unless their plan specifically covers obesity medications.

A patient with obesity but no diabetes asking for Mounjaro will face denial because the prescription is off-label. Asking for Zepbound will also face denial unless their plan covers weight-loss drugs.

This creates a perverse incentive structure where patients with borderline glucose control may pursue a diabetes diagnosis to access tirzepatide, and prescribers may code visits as diabetes management rather than weight management to improve coverage odds.

What most articles get wrong about "different indications"

The common error in published content: treating FDA indication as a biological difference rather than a regulatory and commercial distinction.

The misconception: "Mounjaro is for diabetes, Zepbound is for weight loss, so they work differently in your body."

The reality: Both drugs work identically in your body. GLP-1 receptor activation slows gastric emptying, increases insulin secretion, decreases glucagon secretion, and reduces appetite through central nervous system pathways. GIP receptor activation enhances insulin secretion and may improve lipid metabolism. These mechanisms operate the same way whether you have diabetes, obesity, both, or neither.

The FDA indication reflects the population studied in the phase 3 trials and the primary endpoint the agency evaluated. It does not reflect different formulations, different mechanisms, or different safety profiles.

Evidence: In SURMOUNT-2, which enrolled patients with both obesity and diabetes, tirzepatide produced both A1C reduction (2.07% at 15 mg dose) and weight loss (14.7% at 15 mg dose). A patient in that trial receiving tirzepatide experienced the same drug effect regardless of whether the trial was designed to get diabetes approval or weight-loss approval (Garvey et al., Lancet 2023).

The FDA could have approved tirzepatide under a single brand name with dual indications. Lilly chose the two-brand strategy for commercial reasons: separate sales forces, separate marketing campaigns, separate pricing negotiations with pharmacy benefit managers, and the ability to maintain patent exclusivity longer by staggering approvals.

Patients and prescribers should understand this as a business decision, not a clinical one.

Off-label prescribing: when doctors write Mounjaro for weight loss

Off-label prescribing is legal and common. The FDA approves drugs for specific indications, but once approved, physicians can prescribe them for any medically appropriate use.

The pattern in clinical practice:

From 2022 to late 2023, before Zepbound's approval, prescribers routinely wrote Mounjaro for weight loss in non-diabetic patients. Insurance companies rejected most of these claims, forcing patients to pay cash or appeal. Some appeals succeeded by arguing that obesity is a disease state and Mounjaro's weight-loss efficacy was proven in published trials.

After Zepbound's approval in November 2023, the off-label Mounjaro-for-weight-loss pattern declined because prescribers could now write for Zepbound, the on-label option. But Zepbound's poor insurance coverage meant many patients still couldn't afford it.

Current state (April 2026):

Prescribers continue to write Mounjaro off-label for weight loss in two scenarios:

1. Patients with prediabetes (A1C 5.7% to 6.4%). Prediabetes is not an FDA-approved indication for Mounjaro, but it's close enough to diabetes that some insurers cover it, especially if the patient has other metabolic risk factors.

1. Patients whose insurance covers Mounjaro but not Zepbound. If a patient's plan has a blanket exclusion for weight-loss drugs but covers diabetes drugs, and the patient has any glucose dysregulation, prescribers may write for Mounjaro and code the visit as diabetes prevention or metabolic syndrome management.

This is ethically complex. The prescription is medically appropriate (tirzepatide helps both glucose and weight). The diagnosis coding may be technically accurate (prediabetes is a real condition). But the intent is to navigate insurance restrictions rather than treat the primary diagnosis.

The American Medical Association and the Obesity Medicine Association both support off-label GLP-1 use for obesity treatment and have criticized insurance policies that deny coverage (Kyle et al., Obesity 2024).

The compounded tirzepatide question: how it relates to both brands

Compounded tirzepatide is not Mounjaro. It is not Zepbound. It is tirzepatide acetate powder sourced from bulk API suppliers, reconstituted by a 503B compounding pharmacy, and dispensed in multi-dose vials.

Legal and regulatory status:

The FDA placed tirzepatide on the drug shortage list in December 2022 due to manufacturing capacity constraints at Lilly's facilities. Under Section 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of shortage-list drugs without violating Lilly's patents or FDA exclusivity.

As of April 2026, tirzepatide remains on the shortage list for certain doses, allowing continued compounding. The FDA has signaled it will remove tirzepatide from the list once Lilly's supply stabilizes, which would prohibit further compounding.

Relationship to Mounjaro and Zepbound:

Compounded tirzepatide is chemically identical to the active ingredient in both brands. The difference is formulation and quality assurance:

• Brand-name products undergo full FDA review, including manufacturing inspections, stability testing, and batch-to-batch consistency verification.
• Compounded products are subject to state pharmacy board oversight and periodic FDA inspection of compounding facilities, but do not undergo the same pre-market approval process.

Compounded tirzepatide costs $250 to $400 per month depending on dose and provider, compared to $1,069.08 for brand-name products. For patients without insurance coverage for either Mounjaro or Zepbound, compounded tirzepatide is often the only financially accessible option.

FormBlends clinical pattern:

Across the patient population using compounded tirzepatide through FormBlends-connected providers, the most common scenario is patients who were denied coverage for Zepbound, quoted $900+ per month out-of-pocket, and switched to compounded tirzepatide at $300 to $350 per month. These patients report equivalent weight-loss outcomes and side effect profiles compared to published Zepbound trial data, which aligns with expectations given the identical active ingredient.

The second most common pattern: patients who started on brand-name Mounjaro or Zepbound, achieved initial weight loss, then switched to compounded tirzepatide to reduce long-term costs once they reached a maintenance dose. Continuity of effect is consistently reported in this group.

The compounded option will likely disappear once the FDA removes tirzepatide from the shortage list, forcing patients back to brand-name products or alternative GLP-1 medications like semaglutide.

Side effect profiles: identical mechanisms, identical risks

Because Mounjaro and Zepbound contain the same molecule at the same doses, their side effect profiles are identical. The FDA labels for both products list the same adverse events at the same frequencies.

Most common side effects (occurring in ≥5% of patients):

Side effect	Mounjaro (SURPASS trials)	Zepbound (SURMOUNT trials)
Nausea	12% to 21% (dose-dependent)	18% to 29% (dose-dependent)
Diarrhea	13% to 16%	16% to 21%
Vomiting	5% to 9%	8% to 10%
Constipation	6% to 7%	6% to 11%
Abdominal pain	6% to 9%	8% to 11%
Decreased appetite	5% to 6%	9% to 11%
Dyspepsia	7% to 10%	8% to 9%
Injection site reactions	2% to 4%	2% to 3%

The dose-response relationship is consistent: higher doses produce higher rates of GI side effects. The 15 mg dose has roughly double the nausea rate of the 2.5 mg dose in both trial programs.

Serious adverse events (black box warnings and serious risks):

Both Mounjaro and Zepbound carry identical warnings:

• Thyroid C-cell tumors: Tirzepatide caused thyroid C-cell tumors in rodent studies. Contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
• Pancreatitis: 0.2% incidence in clinical trials. Patients should discontinue if pancreatitis is suspected.
• Hypoglycemia: Risk increases when combined with insulin or sulfonylureas. Dose reduction of concomitant medications may be needed.
• Acute kidney injury: Reported in patients experiencing severe GI side effects leading to dehydration.
• Diabetic retinopathy complications: Rapid glucose improvement may worsen diabetic retinopathy in susceptible patients.
• Gallbladder disease: 1.5% to 2.5% incidence of cholelithiasis (gallstones) across trials, likely related to rapid weight loss.
• Suicidal ideation: Post-market reports of suicidal thoughts in patients on GLP-1 medications, though causality not established. FDA investigating as of 2026.

There is no biological reason for the side effect profile to differ between Mounjaro and Zepbound. Any patient considering either medication should review the same risk-benefit calculus.

Which one should you ask for? The decision tree

Start here: Do you have type 2 diabetes (A1C ≥6.5%) or prediabetes (A1C 5.7% to 6.4%)?

Yes → Ask for Mounjaro.

• Higher likelihood of insurance coverage
• On-label use for diabetes, supportable off-label use for prediabetes
• If your insurance covers Mounjaro but not Zepbound, this is the path of least resistance
• If your insurance covers neither, proceed to compounded tirzepatide evaluation

No → Do you have obesity (BMI ≥30) or overweight with comorbidity (BMI ≥27 plus hypertension, dyslipidemia, or sleep apnea)?

Yes → Ask for Zepbound.

• On-label use for your condition
• If your insurance covers weight-loss medications, Zepbound is the appropriate choice
• If your insurance does not cover weight-loss medications, ask your provider about:
• Compounded tirzepatide (if still available under shortage exemption)
• Semaglutide (Wegovy for weight loss, also poorly covered, or compounded semaglutide)
• Alternative weight-loss medications with better coverage (phentermine/topiramate, naltrexone/bupropion)

No to both → You likely do not meet FDA criteria for either medication.

• Tirzepatide is not approved for general weight management in patients with BMI <27
• Off-label use in this population is not supported by clinical trial data
• Discuss alternative approaches with your provider

Special case: You have both diabetes and obesity, and your insurance covers both Mounjaro and Zepbound.

In this scenario, the choice is arbitrary from a clinical standpoint. Some considerations:

• If your provider is more familiar with Mounjaro (it was approved first), they may prefer to prescribe it.
• If you want your medical record to reflect weight management as the primary treatment goal, Zepbound may be preferable for documentation purposes.
• If you're concerned about prior authorization hassle, Mounjaro may process faster because diabetes coverage is more established.

Special case: Your insurance covers neither, and compounded tirzepatide is available.

Compounded tirzepatide offers the same clinical effect at 70% lower cost. The trade-off is reduced regulatory oversight compared to FDA-approved products. For most patients, this is an acceptable trade-off when the alternative is no treatment due to cost.

FormBlends connects patients with prescribers who can evaluate appropriateness for compounded tirzepatide and pharmacies that meet USP 797 and 795 compounding standards.

The 2026 supply landscape and what it means for access

Current shortage status (April 2026):

The FDA's drug shortage database lists the following tirzepatide doses as in shortage:

• 2.5 mg (intermittent availability)
• 5 mg (available)
• 7.5 mg (intermittent availability)
• 10 mg (available)
• 12.5 mg (in shortage)
• 15 mg (available)

Lilly has stated publicly that it expects to resolve all tirzepatide supply constraints by Q3 2026 as new manufacturing lines come online at its Indiana and Ireland facilities (Lilly investor call, February 2026).

What happens when the shortage ends:

Once the FDA removes tirzepatide from the shortage list, Section 503B compounding pharmacies will no longer be permitted to produce compounded tirzepatide. The FDA has historically given 60 to 90 days' notice before removing a drug from the shortage list to allow patients to transition.

This will force an estimated 300,000 to 500,000 patients currently using compounded tirzepatide (industry estimates, not official counts) to either:

• Switch to brand-name Mounjaro or Zepbound and pay $900+ per month out-of-pocket if uninsured
• Switch to compounded semaglutide (which remains on the shortage list as of April 2026)
• Discontinue GLP-1 therapy

Prediction (falsifiable): By Q4 2026, the FDA will remove tirzepatide from the shortage list. Within 6 months of removal, average weight regain among patients who discontinue due to cost will be 40% to 60% of total weight lost, based on the SURMOUNT-3 placebo-arm data showing 14% regain over 52 weeks (Aronne et al., JAMA 2024). This will create a secondary wave of demand for alternative weight-loss interventions and renewed political pressure to expand insurance coverage for obesity medications.

The Mounjaro vs Zepbound distinction will become less relevant in this scenario because cost, not indication, will be the primary access barrier for most patients.

FAQ

Are Mounjaro and Zepbound the same drug? Yes. Both contain tirzepatide at identical doses (2.5 mg through 15 mg) manufactured by Eli Lilly. The only difference is FDA indication: Mounjaro for type 2 diabetes, Zepbound for chronic weight management. The molecular formulation, delivery device, and side effects are identical.

Why did Eli Lilly create two different brand names for the same drug? Separate brand names allow Lilly to market to different patient populations, navigate different insurance formularies, and maintain distinct pricing and rebate strategies. It's a commercial decision, not a clinical one. The drug works the same way in your body regardless of the name on the box.

Can I use Mounjaro for weight loss if I don't have diabetes? Legally, yes, as an off-label prescription. Practically, most insurance companies will deny coverage for Mounjaro if you don't have diabetes. You would need to pay out-of-pocket ($1,069/month) or appeal the denial. Zepbound is the on-label option for weight loss, though it also has limited insurance coverage.

Can I use Zepbound if I have diabetes? Yes. Zepbound works for glucose control just as effectively as Mounjaro. In the SURMOUNT-2 trial, patients with diabetes on Zepbound achieved 2.07% A1C reduction. However, insurance may deny Zepbound for diabetes because Mounjaro is the on-label option for that indication.

Which one is more effective for weight loss? Neither. They contain the same active ingredient at the same doses. Weight-loss outcomes in SURMOUNT trials (Zepbound) and SURPASS trials (Mounjaro) are nearly identical when comparing the same doses in similar patient populations. At 15 mg, expect 15% to 21% total body weight loss over 72 weeks.

Which one is more effective for lowering blood sugar? Neither. A1C reduction in SURPASS trials (Mounjaro) and SURMOUNT trials (Zepbound) are nearly identical. At 15 mg, expect 2.0% to 2.5% A1C reduction in patients with baseline A1C around 8.0% to 8.5%.

Does one have fewer side effects than the other? No. The side effect profiles are identical because the drug is identical. Nausea, diarrhea, and vomiting are the most common side effects for both, occurring in 12% to 29% of patients depending on dose. Serious risks (pancreatitis, thyroid tumors in rodents, gallbladder disease) are the same.

Is compounded tirzepatide the same as Mounjaro and Zepbound? Compounded tirzepatide contains the same active ingredient but is not FDA-approved. It's produced by compounding pharmacies under state oversight, not by Eli Lilly. Quality control standards are lower than for FDA-approved products, but the molecule is chemically identical. Cost is 70% lower ($250 to $400/month vs $1,069/month).

Will my insurance cover Mounjaro or Zepbound? Mounjaro: likely covered if you have type 2 diabetes and meet prior authorization criteria (usually A1C ≥7.0% and trial of metformin). Zepbound: covered by only 25% of commercial plans as of 2026. Medicare does not cover either for weight loss by federal law. Check your specific plan formulary.

Can I switch from Mounjaro to Zepbound or vice versa? Yes, seamlessly. Because they're the same drug, you can switch at the same dose without re-titration. If you're on Mounjaro 10 mg and switch to Zepbound 10 mg, continue your normal weekly injection schedule. Notify your prescriber for prescription and insurance coordination.

What happens if I can't afford either Mounjaro or Zepbound? Options: (1) Apply for Lilly's patient assistance program (income-based, free medication for qualifying patients). (2) Use the Lilly savings card ($150/month off, available for commercially insured patients, not Medicare). (3) Ask about compounded tirzepatide if still available under FDA shortage exemption. (4) Consider alternative GLP-1 medications like semaglutide, which may have different coverage. (5) Discuss non-GLP-1 weight-loss medications with better insurance coverage.

Is one safer than the other? No. They carry identical risks because they're the same molecule. Both have black box warnings for thyroid C-cell tumors (based on rodent data). Both carry risks of pancreatitis, gallbladder disease, and hypoglycemia when combined with other diabetes medications. Safety profile is identical.

Sources

1. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
2. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. New England Journal of Medicine. 2021.
3. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
4. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021.
5. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. Lancet Diabetes Endocrinology. 2022.
6. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
7. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
8. Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-3 randomized clinical trial. JAMA. 2024.
9. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. Nature Medicine. 2023.
10. Kyle TK et al. Regarding Medicare coverage of anti-obesity medications. Obesity. 2024.
11. U.S. Food and Drug Administration. Drug Shortages Database: Tirzepatide. Accessed April 2026.
12. IQVIA Institute for Human Data Science. Medicine Spending and Affordability in the United States. 2026.
13. Kaiser Family Foundation. Employer Health Benefits Survey 2025: Coverage of Weight-Loss Medications. 2025.
14. Eli Lilly and Company. Q4 2025 Earnings Call Transcript. February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.